Lifeboat Foundation

Groundbreaking graphene neurotechnology developed by ICN2 and collaborators promises transformative advances in neuroscience and medical applications, demonstrating high-precision neural interfaces and targeted nerve modulation.

A study published in Nature Nanotechnology presents an innovative graphene-based neurotechnology with the potential for a transformative impact in neuroscience and medical applications. This research, spearheaded by the Catalan Institute of Nanoscience and Nanotechnology (ICN2) together with the Universitat Autònoma de Barcelona (UAB) and other national and international partners, is currently being developed for therapeutic applications through the spin-off INBRAIN Neuroelectronics.

Key Features of Graphene Technology.

Some dairy farms could turn into lifesaving insulin factories.

LatestPaper “Exploring beyond Common Cell Death Pathways in Oral Cancer: A Systematic Review” is now available.

Special Issue in journal Biology: Cell Self-Destruction (Programmed Cell Death), Immunonutrition and Metabolism.

❤️🔬🧬

Researchers unveil the complex cellular architecture of the heart using advanced RNA sequencing and imaging techniques, shedding light on the intricate organization of heart cells and their developmental pathways.

Analyzing cells from patients with neuromyelitis optica spectrum disorder, researchers show transfers of patient-derived extracellular vesicles rich in the apolipoprotein APOE alleviate neuroinflammation and slow astrocyte loss in a mouse model of this severe autoimmune disease.

📄 :

APOE was augmented in astrocytic extracellular vesicles from patients with neuromyelitis optica spectrum disorder and decreased brain lesions in a mouse model.

Research involving mice and samples from patients with multiple sclerosis reveals how anti-CD20 antibodies such as ocrelizumab protect neurons in gray matter, and ties the treatment’s effects to elevated levels of BAFF.

Preventative, predictive and personalized healthcare and longevity — dr. william kapp, MD — CEO, fountain life.

Dr. William Kapp, MD is Chief Executive Officer of Fountain Life (https://fountainlife.com/about/), a company focused on transforming the current healthcare system into one that is both proactive and data-driven, enabling enhanced longevity and catching and treating illnesses earlier than ever before, focusing on the detection and reversal of asymptomatic diseases and advancing an entirely new healthcare paradigm.

Continue reading “Dr. William Kapp, MD — CEO, Fountain Life — Preventative, Predictive, Personalized Healthcare” »

“For 12 years I’ve been trying to get back my feet. Now I have learned how to walk normal, natural.”

A paralyzed man is walking again thanks to a “digital bridge” researchers created between his brain and a spinal stimulator.

“For 12 years I’ve been trying to get back my feet,” the 40-year-old Dutch man, Gert-Jan Oskam, told reporters on May 23. “Now I have learned how to walk normal, natural.”

Continue reading “Paralyzed man walks again using only his thoughts” »

Globally, the number of people living with, or dying from, neurological conditions such as stroke, Alzheimer’s disease and other dementias, and meningitis has risen substantially over the past 30 years due to the growth and aging of the global population as well as increased exposure to environmental, metabolic, and lifestyle risk factors. In 2021, 3.4 billion people experienced a nervous system condition, according to a major new analysis from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021, published in The Lancet Neurology.

The analysis suggests that worldwide, the overall amount of disability, illness, and premature death —a measurement known as disability-adjusted life years (DALYs)—caused by neurological conditions increased by 18% over the past 31 years, rising from around 375 million years of healthy life lost in 1990 to 443 million years in 2021.

The absolute number of DALYs is increasing in large part due to aging and growing populations worldwide.